12:00 AM
 | 
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vargatef nintedanib: Phase II data

An open-label, international Phase II trial in 96 evaluable previously untreated patients with advanced, unresectable or recurrent clear cell RCC showed that there was no significant difference between patients receiving twice-daily 200 mg nintedanib and once-daily 50 mg sunitinib on the primary endpoint of PFS rate at 9 months (43% vs. 45%, p=0.85). Additionally, there were no...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >